SAN FRANCISCO, March 08, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Caterpillar, Inc. (NYSE:CAT) to the securities class action pending in the United States District Court for the Northern District of Illinois and to the May 2, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of CAT between February 19, 2013 and March 1, 2017 and suffered over $100,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/CAT
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On March 2, 2017, law enforcement officials executing a search warrant raided Caterpillar’s headquarters. Federal agents reportedly seized documents related to a criminal investigation into whether the Company wrongfully shifted profits overseas and to offshore shell companies to avoid paying more than $2 billion in U.S. taxes. This news drove the price of Caterpillar’s shares down approximately 4.28% to close at $94.36 per share on March 2, 2017.
On March 8, 2017, The New York Times published an article entitled “Caterpillar Is Accused In a Report Of Fraud.” The article concerns a report commissioned by the government and quoted its author. According to the Times, the author wrote, “Caterpillar did not comply with either U.S. tax law or U.S. financial reporting rules[]”, “I believe that the company’s noncompliance with these rules was deliberate and primarily with the intention of maintaining a higher share price[]”, and “[t]hese actions were fraudulent rather than negligent.” This news has driven the price of Caterpillar’s shares down approximately 2% during intraday trading.
“We’re concerned about earlier Company and management statements regarding cooperation with Federal officials in the context of the reported raid and whether Defendants overstated the Company’s income,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding CAT should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



